Intravitreal Bevacizumab for Inflammatory Neovascular Membranes
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to
intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and
evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence
Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous
Choroidopathy and 1 patient with Multifocal Choroiditis.